Table 6. Comparison of patients who... | American Society of Hematology

Table 6.

Comparison of patients who underwent autograft conditioned with high-dose melphalan or busulphan and cyclophosphamide: group 1, daunorubicin

	Mel n = 26	BU/CY n = 33	Total DFS, % n = 62	Mel DFS, %	BU/CY DFS, %	P, Mel vs BU/CY
French-American-British
M0	1	0	100	100	—	—
M1	6	8	40	17	50	.19
M2	4	6	55	75	50	.44
M3	4	5	78	100	60	.18
M4	2	7	5	100	29	.16
M4Eo	2	0	100	100	—	—
M5	7	6	62	71	50	.32
M6	0	0	—	—	—	—
M7	0	1	100	—	100	—
Age, y
0-5	9	15	64	78	60	.33
6-10	11	8	50	73	25	.04^6-150
11-15	6	10	58	50	53	.57
Central nervous system disease
No	24	32	58	71	49	.13
Yes	2	1	67	50	100	.48
Cytogenetics
Good	4	4	63	75	50	.92
Poor	6	1	67	67	100	.54
Standard	14	20	50	64	40	.15

	Mel n = 26	BU/CY n = 33	Total DFS, % n = 62	Mel DFS, %	BU/CY DFS, %	P, Mel vs BU/CY
French-American-British
M0	1	0	100	100	—	—
M1	6	8	40	17	50	.19
M2	4	6	55	75	50	.44
M3	4	5	78	100	60	.18
M4	2	7	5	100	29	.16
M4Eo	2	0	100	100	—	—
M5	7	6	62	71	50	.32
M6	0	0	—	—	—	—
M7	0	1	100	—	100	—
Age, y
0-5	9	15	64	78	60	.33
6-10	11	8	50	73	25	.04^6-150
11-15	6	10	58	50	53	.57
Central nervous system disease
No	24	32	58	71	49	.13
Yes	2	1	67	50	100	.48
Cytogenetics
Good	4	4	63	75	50	.92
Poor	6	1	67	67	100	.54
Standard	14	20	50	64	40	.15

Cytogenetics results were available for 51 of 62 group 1 patients. Ten patients received conditioning other than Mel or BU/CY. See ”Results” for outcomes.

Mel indicates melphalan; BU/CY, busulphan and cyclophosphamide.

F6-150

P < .05

View Large

This Feature Is Available To Subscribers Only